PBYI Puma Biotechnology, Inc.
Healthcare$7.27+2.68%ClosedMarket Cap: $370.0M
As of 2026-05-26
Valuation
P/E (TTM)
11.41
PEG
4.35
P/B
2.80
P/S
1.59
EV/EBITDA
7.77
DCF Value
$16.70
FCF Yield
14.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
74.5%
Operating Margin
13.0%
Net Margin
10.7%
ROE
20.4%
ROA
12.7%
ROIC
17.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $44.8M | 76.7% | $-3.8M | $-3.8M | $— | — |
| Q4 null | $75.5M | 69.3% | $17.1M | $13.4M | $— | — |
| FY null | $228.4M | 74.5% | $37.3M | $31.1M | $— | — |
| Q3 null | $54.5M | 77.7% | $9.6M | $8.8M | $— | — |
| Q2 null | $52.4M | 76.5% | $6.6M | $5.9M | $— | — |
| Q1 null | $46.0M | 77.1% | $4.0M | $3.0M | $— | — |
| Q4 null | $59.1M | 76.4% | $13.4M | $19.3M | $— | — |
| FY null | $230.5M | 72.1% | $31.0M | $30.3M | $— | — |
| Q3 null | $80.5M | 63.9% | $22.1M | $20.3M | $— | — |
| Q2 null | $47.1M | 77.4% | $-2.2M | $-4.5M | $— | — |
| Q1 null | $43.8M | 75.5% | $-2.3M | $-4.8M | $— | — |
| Q4 2023 | $72.2M | 66.3% | $14.8M | $12.3M | $0.26 | — |